RedHill Biopharma Announces Initiation of Phase II Study with YELIVA™ in Hepatocellular Carcinoma at the Medical University of South Carolina
The Phase II clinical study is intended to evaluate the efficacy and safety of YELIVA™ (ABC294640) in patients with advanced…